Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6810247 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL6805700 | 0.87 | SMN1; SMN2 (0.46) | SMN1; SMN2ADRA1AHRH1ADRA1B | |
| SCHEMBL6632459 | 0.84 | BTK (0.33) | ALDH1A1BTKADRA1AHRH1ADRA1B | |
| SCHEMBL6629342 | 0.81 | MEN1 (0.36) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL6806899 | 0.81 | MEN1 (0.36) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL6629463 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL6629811 | 0.75 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL28038421 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL6357080 | 0.70 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL28038719 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1368352-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | Pfizer Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002074774-A1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | SMN1; SMN2 2159/4885MEN1 1517/4885POLB 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.